1. Generics Bulletin
  2. >>Products
  3. >>Generics

Mylan Draws Hope From FDA’s Fluticasone Labelling Update

 
• By Aidan Fry

Mylan sees supplemental labelling updates made by the FDA for all fluticasone-based medicines as a sign that approval for its Advair generic may be imminent. 

RedFlag
Mylan sees no 'red flags' barring FDA approval of its generic rival to GSK's Advair Diskus inhaler • Source: Shutterstock

Labelling updates implemented by the US Food and Drug Administration (FDA) on 7 January for all medicines containing fluticasone have given Mylan fresh hope that US approval for its generic rival to GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) blockbuster may be imminent.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.